Kairos Pharma Ltd. (NYSE American: KAPA), an oncology therapeutics company based in Los Angeles, announced that its CEO and Chairman Dr. John Yu will present at the 16th Annual LD Micro Invitational on May 18, 2026, at 1:00 p.m. PDT. The presentation will take place at the Luxe Sunset Boulevard Hotel in Los Angeles, where Dr. Yu will provide an update on the company’s clinical program and partnering activities. The full press release is available here.
Kairos Pharma is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. The company’s lead candidate, ENV-105, is an antibody that targets CD105—a protein identified as a key driver of resistance and disease relapse in response to standard therapy. ENV-105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types.
Currently, ENV-105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer aimed at addressing significant unmet medical needs. As of the date of the press release, ENV-105 has not been approved as safe or effective by the United States Food and Drug Administration or any other comparable foreign regulator.
The LD Micro Invitational is a key event for emerging growth companies, providing a platform to present to a broad audience of investors, analysts, and industry professionals. Dr. Yu’s presentation is expected to detail progress in the clinical trials and potential partnering opportunities, which could be pivotal for the company’s development and future funding. For investors, the update offers insight into the company’s trajectory in addressing drug resistance in cancer, a major challenge in oncology.
Kairos Pharma’s focus on CD105 marks a novel approach to tackling resistance mechanisms that limit the efficacy of standard treatments. If successful, ENV-105 could have a significant impact on treatment paradigms for prostate and lung cancers, among others. The company’s participation in the conference underscores its commitment to advancing its pipeline and engaging with the investment community. For more information on Kairos Pharma, visit the company’s newsroom at https://ibn.fm/KAPA.
The announcement comes as the biotech sector continues to see heightened interest in innovative cancer therapies. Kairos Pharma’s presentation may attract attention from potential partners and investors looking for breakthroughs in drug resistance. The company’s clinical data updates will be closely watched by analysts and stakeholders.
